Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hualan Biological Engineering Inc. (002007.SZ)
Xinxiang, CN
Hualan Biological Engineering Inc. operates as a biopharmaceutical company, specializing in the research, development, production, and commercialization of a diverse portfolio of medical products within the People's Republic of China. Its offerings span plasma-derived therapies, various viral and bacterial vaccines, recombinant proteins, and other advanced biologics. The company's extensive range of plasma products includes essential components like human albumin, a broad spectrum of human immunoglobulins (such as intravenous, rabies, hepatitis B, and tetanus formulations), and vital coagulation factors like human prothrombin complex and factor VIII. Hualan also provides specialized solutions such as lyophilized human thrombin for external use and surgical fibrin glue. In its vaccine division, Hualan offers critical immunizations, including several influenza vaccines (e.g., split virus, A H1N1, and quadrivalent forms), recombinant hepatitis B vaccine, and ACYW135 meningococcal polysaccharide vaccine. The company actively pursues strategic collaborations with key scientific organizations, most notably the Chinese Academy of Sciences, as well as other esteemed research institutes and enterprises. Established in 1992, Hualan Biological Engineering Inc. is headquartered in Xinxiang, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.15% | -1.29% | -5.50% | -11.18% | -11.75% | -9.19% | -14.92% | -39.04% | -65.99% | -11.01% | +3,841.14% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | -1 |
| Buy | 6 | 0 |
| Hold | 1 | +1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+4.5% ★ Q1'26: -12.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-11.9% Q1'26: -23.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+13.0% Q1'26: -7.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+24.7% ★ Q1'26: +38.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+10.0% ★ Q1'26: +9.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.1% ★ Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.39× ★ Q1'26: 0.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 6 Rev. Ana. 6 EPS Ana. |
Dec 2028 2 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.47B
est: 1.51B (-2.6%)
|
1.93B
est: 1.93B (+0.0%)
|
2.37B
est: 2.33B (+1.7%)
|
3.22B
est: 3.16B (+1.6%)
|
3.70B
est: 3.76B (-1.5%)
|
5.02B
est: 4.89B (+2.7%)
|
4.44B
est: 5.73B (-22.6%)
|
4.52B
est: 5.01B (-9.8%)
|
5.34B
est: 5.40B (-1.1%)
|
4.38B
est: 5.06B (-13.4%)
|
4.58B
est: 4.73B (-3.2%)
|
4.65B
4.06B – 5.00B
-1.7% YoY
|
5.01B
4.01B – 5.57B
+7.8% YoY
|
5.34B
4.45B – 5.84B
+6.5% YoY
|
| EBITDA |
691.94M
est: 568.86M (+21.6%)
|
922.89M
est: 728.21M (+26.7%)
|
976.59M
est: 876.71M (+11.4%)
|
1.33B
est: 1.19B (+11.5%)
|
1.60B
est: 1.41B (+12.8%)
|
2.18B
est: 1.84B (+18.4%)
|
1.78B
est: 2.16B (-17.4%)
|
1.50B
est: 1.89B (-20.7%)
|
2.07B
est: 2.03B (+1.7%)
|
1.44B
est: 1.78B (-19.1%)
|
1.41B
est: 1.66B (-15.1%)
|
1.63B
1.43B – 1.76B
-1.7% YoY
|
1.76B
1.41B – 1.96B
+7.8% YoY
|
1.88B
1.57B – 2.05B
+6.5% YoY
|
| EBIT |
574.64M
est: 493.74M (+16.4%)
|
779.23M
est: 632.04M (+23.3%)
|
830.13M
est: 760.92M (+9.1%)
|
1.19B
est: 1.03B (+15.0%)
|
1.43B
est: 1.23B (+16.9%)
|
2.00B
est: 1.60B (+25.0%)
|
1.59B
est: 1.87B (-15.3%)
|
1.22B
est: 1.64B (-25.3%)
|
1.81B
est: 1.77B (+2.5%)
|
1.18B
est: 1.50B (-21.5%)
|
1.13B
est: 1.40B (-19.5%)
|
1.38B
1.20B – 1.48B
-1.7% YoY
|
1.49B
1.19B – 1.65B
+7.8% YoY
|
1.58B
1.32B – 1.73B
+6.5% YoY
|
| Net Income |
589.12M
est: 626.40M (-6.0%)
|
780.31M
est: 791.08M (-1.4%)
|
820.82M
est: 853.60M (-3.8%)
|
1.14B
est: 1.14B (+0.3%)
|
1.28B
est: 1.30B (-1.4%)
|
1.61B
est: 1.66B (-2.6%)
|
1.30B
est: 1.81B (-28.3%)
|
1.08B
est: 1.39B (-22.7%)
|
1.48B
est: 1.40B (+5.6%)
|
1.09B
est: 1.32B (-17.7%)
|
940.40M
est: 1.21B (-22.4%)
|
1.03B
1.02B – 1.04B
-15.2% YoY
|
1.16B
975.05M – 1.65B
+13.4% YoY
|
1.33B
1.04B – 1.49B
+14.1% YoY
|
| SGA |
228.48M
est: 385.80M (-40.8%)
|
337.27M
est: 493.87M (-31.7%)
|
426.14M
est: 594.58M (-28.3%)
|
719.14M
est: 808.21M (-11.0%)
|
737.87M
est: 959.01M (-23.1%)
|
1.33B
est: 1.25B (+6.4%)
|
1.01B
est: 1.46B (-30.9%)
|
1.21B
est: 1.28B (-5.8%)
|
1.47B
est: 1.38B (+6.2%)
|
1.07B
est: 1.25B (-14.5%)
|
1.01B
est: 1.17B (-13.6%)
|
1.15B
1.00B – 1.23B
-1.7% YoY
|
1.23B
988.69M – 1.37B
+7.8% YoY
|
1.32B
1.10B – 1.44B
+6.5% YoY
|
| EPS |
0.32
est: 0.34 (-6.6%)
|
0.43
est: 0.43 (-0.6%)
|
0.45
est: 0.47 (-3.6%)
|
0.63
est: 0.62 (+1.4%)
|
0.70
est: 0.71 (-1.7%)
|
0.89
est: 0.91 (-1.7%)
|
0.71
est: 0.99 (-28.4%)
|
0.59
est: 0.76 (-22.5%)
|
0.81
est: 0.77 (+5.6%)
|
0.60
est: 0.72 (-17.2%)
|
0.52
est: 0.66 (-21.6%)
|
0.56
0.56 – 0.57
-15.2% YoY
|
0.64
0.53 – 0.90
+13.4% YoY
|
0.73
0.57 – 0.82
+14.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X China Biotech ETF (HKD) 2820.HK | 1.09% | 870.7K | 0.68% |
| 2 | WisdomTree Emerging Markets SmallCap Dividend UCITS ETF DGSD.L | 0.26% | 113.1K | 0.54% |
| 3 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.13% | 2.37M | 0.58% |
| 4 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.13% | 47.9K | 0.65% |
| 5 | HSBC MSCI China A UCITS ETF HMCT.L | 0.08% | 104.1K | 0.30% |
| 6 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.05% | 7.7K | 0.65% |
| 7 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.03% | 23.0K | 0.55% |
| 8 | State Street SPDR S&P China ETF GXC | 0.02% | 71.4K | 0.59% |
| 9 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 157.9K | 0.19% |
| 10 | Franklin Emerging Market Core Dividend Tilt Index ETF DIEM | 0.01% | 6.4K | 0.19% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bao Xian Zhang | Deputy GM & Director | — | male |
| Bei Fan | GM & Director | — | female |
| Jun Liu | Deputy General Manager | — | female |
| Jun Min Xie | Chief Financial Officer & Secretary of the Board of Directors | — | male |
| Ping Lin | CFO & Accounting Supervisor | — | female |
| Xiao Wei Ma | Executive Deputy General Manager | — | male |
| Yuancheng Lou | Board Secretary | — | male |
| Zhengyue Chen | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002007.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
